Back to top
more

Ironwood Pharmaceuticals (IRWD)

(Delayed Data from NSDQ)

$7.82 USD

7.82
2,782,954

-0.26 (-3.22%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $7.81 -0.01 (-0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for IRWD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Ironwood Pharmaceuticals, Inc. [IRWD]

Reports for Purchase

Showing records 1001 - 1015 ( 1015 total )

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 1001

04/23/2012

Daily Note

Pages: 4

Linaclotide PDUFA Delay - Reiterate UNDERPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 1002

03/05/2012

Company Report

Pages: 8

Downgrading to UNDERPERFORM; Updated Launch Expenses Leads to Significant Anticipated Funding Gap

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 1003

01/05/2012

Company Report

Pages: 8

Acquires Rights to BNC210 - A Potential Blockbuster for Anxiety and Depression

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 1004

11/08/2011

Company Report

Pages: 7

Q3 Results - Linaclotide PDUFA June 2012

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 1005

10/04/2011

Industry Report

Pages: 24

Biotechnology/Biopharmaceuticals/BioDefense: October 2011 Potential Milestones & Key Events - Monthly Update.

Provider: WEDBUSH SECURITIES INC.

Price: 75.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 1006

09/29/2011

Daily Note

Pages: 4

Partner Almirall Submits MAA in the EU for Linaclotide, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 1007

08/11/2011

Company Report

Pages: 5

Q2:11 EPS Uneventful, Next Up Is EU Linaclotide Submission

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 1008

08/01/2011

Industry Report

Pages: 20

August 2011 Potential Milestones & Key Events - Monthly Update

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 50.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 1009

05/25/2011

Company Report

Pages: 54

We initiate coverage of Ironwood with a Hold rating

Provider: DUNCAN-WILLIAMS, INC.

Analyst: RIVKIND I

Price: 100.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 1010

05/13/2011

Company Report

Pages: 5

Q1:11 EPS Uneventful, NDA Remains on Track for Q3

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 1011

03/03/2011

Company Report

Pages: 5

Q4 EPS a Non-Event, Linaclotide NDA Filing on Track for Q3:11

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 1012

11/02/2010

Company Report

Pages: 5

Announces Positive Phase III results for Linaclotide in Patients with IBS with Constipation

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 1013

09/14/2010

Company Report

Pages: 4

Announces Positive Phase III Results for Linaclotide in Patients with IBS with Constipation

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 1014

08/18/2010

Company Report

Pages: 8

Q2:10 Update - to Add a New Co-Primary Endpoint to the IBS-C Phase III Studies

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 1015

03/16/2010

Company Report

Pages: 16

Play Ironwood to Reach Green-Initiating with OUTPERFORM and $24 price target

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 50.00

Research Provided by a Third Party